PRCT Stock Forecast & Price Target

PROCEPT BioRobotics is viewed favorably because its Aquabeam and HYDROS robotic systems address a large BPH market and the company is demonstrating real commercial traction through Q1 sales of $83.1M, up 20% year over year, with domestic HYDROS placements and higher-than-expected ASPs driving the beat. The company also showed improving operating quality, with gross margin of 65% and an adjusted EBITDA loss of $18M both ahead of expectations, while management reiterated 2026 revenue guidance of $390M-$410M and procedure growth of 39%-48%, signaling confidence in continued scaling. Even with concerns around sales force restructuring and reimbursement pressure in adjacent therapies, strong capital placements, inventory normalization, and an enrollment pace ahead of schedule in the prostate cancer study support the view that PROCEPT BioRobotics has multiple pathways to sustain growth and expand beyond the current market’s expectations.

PROCEPT BioRobotics is facing a weakening fundamental setup as procedure growth has slowed over the last 4 qtrs, with rising PAE adoption and sales force restructuring under new leadership creating execution uncertainty, while 1Q procedures missed expectations and management’s Q2 revenue midpoint came in about $2M below the Street, implying a steeper-than-usual back-half ramp to reach 2026 procedure guidance. The company’s valuation remains stretched at roughly 2x EV/Sales despite a -32% YTD stock move, yet the thesis is undermined by the risk that PAE headwinds intensify into 2027 as the ASC for PAE is set to increase 30% and Aquablation is not widely performed there, limiting near- to medium-term utilization upside. Although domestic capital placements were strong and ASP reached an all-time high, these positives are offset by constrained hospital capital spending, potential limits to Aquablation adoption beyond early adopters, and uncertainty that utilization per system will grow as projected, leaving the stock vulnerable until clearer evidence emerges that sales initiatives can sustainably improve demand.